### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

#### (19) World Intellectual Property Organization International Bureau



# 

(43) International Publication Date 6 November 2003 (06.11.2003)

PCT

#### (10) International Publication Number WO 2003/091264 A3

(51) International Patent Classification7: 9/40, A61K 31/4155

C07F 9/38,

(21) International Application Number:

PCT/US2003/012926

(22) International Filing Date: 25 April 2003 (25.04.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

26 April 2002 (26.04.2002) US 60/375,665 26 April 2002 (26.04.2002) US 60/375,834 60/375,779 26 April 2002 (26.04.2002) US 26 April 2002 (26.04.2002) US 60/375,622

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

60/375,665 (CON) US 26 April 2002 (26.04.2002) Filed on 60/375,834 (CON) US 26 April 2002 (26.04.2002) Filed on 60/375,779 (CON) US 26 April 2002 (26.04.2002) Filed on 60/375,622 (CON) US 26 April 2002 (26.04.2002) Filed on

(71) Applicant (for all designated States except US): GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHEN, James, M. [US/US]; 4015 Marblehead Drive, San Ramon, CA 94583 (US). CHEN, Xiaowu [US/US]; 377 Laurie Meadows Drive, Apt. 319, San Mateo, CA 94403 (US). KIM, Choung, U. [US/US]; 1750 Elizabeth Street, San Carlos, CA 94070 (US). LEE, William, A. [US/US]; 749 Anderson Drive, Los Altos, CA 94024 (US). LEE, Christopher, P. [US/US]; 65 Hermann Street, #5, San Francisco, CA 94102 (US). TARIO, James, D. [US/US]; 142 Elm Street, Apt. 205, San Mateo, CA 94401 (US). XU, Lianhong [US/US]; 640 Hobart Avenue, San Mateo, CA 94402 (US). NELSON, Peter, H. [US/US]; 42 San Juan Court, Los Altos, CA 94022 (US).

- (74) Agents: ANDRUS, Alex et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 11 March 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

(57) Abstract: Phosphorus-substituted imidazole compounds with anti-HIV properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit reverse transcriptase activity and are useful therapeutically for the inhibition of such enzymes, as well as in assays for the detection of such enzymes.



PCT/US 03/12926

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07F9/38 C07F9/40

A61K31/4155

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07F A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

#### EPO-Internal

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Υ	WO 01 96329 A (SHINOGI & CO., LTD) 20 December 2001 (2001-12-20)	1-7, 20-90, 161-168
Ρ,Υ	page 24, line 13 - line 14 & EP 1 295 879 A (SHIONOGI & CO) 26 March 2003 (2003-03-26) the whole document	1-7, 20-90, 161-168
Υ	WO 02 03997 A (GIRARDET JEAN LUC ;ICN PHARMACEUTICALS (US); PIETRZKOWSKI ZBIGNIEW) 17 January 2002 (2002-01-17)	1-7, 20-90, 112-138, 140-147, 161-168
	page 3, line 6 -page 7, line 12; claims 6,15 	
	-/	

X Further documents are listed in the continuation of box C.	X Patent family members are listed in annex.			
Special categories of cited documents:      A* document defining the general state of the art which is not considered to be of particular relevance      E* earlier document but published on or after the international filling date      C* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)      O* document referring to an oral disclosure, use, exhibition or other means      P* document published prior to the international filling date but later than the priority date claimed	<ul> <li>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>"&amp;" document member of the same patent family</li> </ul>			
Date of the actual completion of the international search	Date of mailing of the international search report			
4 December 2003	2 3. 01. 2004			
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk	Authorized officer			
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Richter, H			



(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
ategory °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 312 662 B1 (ROBINSON EDWARD D ET AL) 6 November 2001 (2001-11-06)	1-7, 20-90, 112-138, 140-147, 161-168
	column 43, line 27 -column 50, line 10; claim 1	
Y	US 5 413 996 A (BODOR NICHOLAS S) 9 May 1995 (1995-05-09)	1-7, 20-90, 112-138, 140-147, 161-168
	the whole document	
Ρ,Χ	MENENDEZ-ARIAS L: "Targeting HIV: antiretroviral therapy and development of drug resistance" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 8, 1 August 2002 (2002-08-01), pages 381-388, XP004386181 ISSN: 0165-6147 the whole document	1-7,13, 20-90, 161-168
X	VIELHABER, BERND: "Bericht vom 3rd International Workshop on Salvage Therapy for HIV-Infection, 12-14. April 2000, Chicago, Teil I" DEUTSCHE AIDS-HILFE E.V. FAXREPORT ZU HIV UND AIDS, no. 9 and 10, - 29 May 2000 (2000-05-29) pages 1-12, XP002247382 Berlin page 3, column 1, line 1 - line 23	1-3, 161-168
Y	CLERCQ DE E: "NEW DEVELOPMENTS IN ANTI-HIV CHEMOTHERAPY" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 8, no. 13, November 2001 (2001-11), pages 1543-1572, XP009012547 ISSN: 0929-8673 page 1556 -page 1557	1-7, 26-90, 161-168
X	WO 01 17982 A (PIANETTI PASCAL MAURICE CHARLE; GLAXO GROUP LTD (GB); FREEMAN GEOR) 15 March 2001 (2001-03-15) page 30, line 21 -page 33, line 28; claims 1-37	1-7,14, 20-90, 161-168

	PC1/US 03/12926				
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT  A. Charter of decument, with indication where appropriate, of the relevant passages  Relevant to claim No.					
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Helevari to Claim No.			
Υ	EP 0 786 455 A (SHIONOGI & CO) 30 July 1997 (1997-07-30)	1-7, 20-90, 112-138, 140-147, 161-168			
	claims 7,8; tables 5,6 				

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. X Claims Nos.: 169-224, 229-232 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  See FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4-7, 13, 14, 91-138, 140-160, partly: 1-3, 20-90, 161-168
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest X The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 3.

Claims Nos.: 169-224, 229-232

In claim 169, "MBF" is not clear to the skilled person; see for instance WO-A-0114361: Example 2: Preparation of Monobenzyl fluorescein (MBF)"

There is no category for a claim directed to an "improvement"; see claim 170 in connection with Guidelines Ch. III. 3.1.

Apart from the fact that the expression "improvement" as such is unclear, the claims 171-201 attempt to define the subject-matter in terms of that unclear result to be achieved which merely amounts to a statement of the underlying (unclear) problem. The technical features necessary for achieving this result should have been added.

Likewise, claims 211 - 220 attempt to define the subject-matter in terms of the result to be achieved which merely amounts to a statement of the underlying problem. The technical features necessary for achieving this result should have been added.

The meaning of "half-life" in claim 232 is not precise; see Guidelines Ch. IV. 4.5.

A claim should be understandable without reference to the description. Therefore, claims 169, 202-210, 221 - 224, and 229-231 cannot be accepted unter Art. 6, PCT; Rule 6.2(a) and Guidelines Ch. III. 4.10.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 6, 91-111, 132, 134, 140-147, partly claims 1-3, 20-90, 161-168

Capravirine-like phosphonate NNRTI compounds

- 2. Claims: 4, 133, partly claims 1-3, 20-90, 161-168

  Phosphonate compounds of formula Ia
- 3. Claims: 5, 112-131, 135-138, 148-160, partly claims 1-3, 20-90, 161-168

Phosphonate compounds of formula Ib

- 4. Claims: 7, partly claims 1-3, 20-90, 161-168

  Phosphonate compounds of formula Id
- 5. Claims: 8, partly claims 1-3, 20-90, 161-168

  PETT-like phosphonate NNRTI compounds
- 6. Claims: 9, partly claims 1-3, 20-90, 161-168

  Pyrazole-like phosphonate NNRTI compounds
- 7. Claims: 10, partly claims 1-3, 20-90, 161-168
  Urea-PETT-like phosphonate NNRTI compounds
- 8. Claims: 11, partly claims 1-3, 20-90, 161-168

  Nevapirine-like phosphonate NNRTI compounds
- 9. Claims: 12, partly claims 1-3, 20-90, 161-168

  Quinazoline-like phosphonate NNRTI compounds
- 10. Claims: 13, partly claims 1-3, 20-90, 161-168

  Evavirenz-like phosphonate NNRTI compounds

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

- 11. Claims: 14, partly claims 1-3, 20-90, 161-168

  Benzophenone-like phosphonate NNRTI compounds
- 12. Claims: 15, partly claims 1-3, 20-90, 161-168

  Pyrimidine-like phosphonate NNRTI compounds
- 13. Claims: partly 1-3, 16, 20-90, 161-168
  SJ-3366-like phosphonate NNRTI compounds
- 14. Claims: 17, partly claims 1-3, 20-90, 161-168

  Delavirdine-like phosphonate NNRTI compounds
- 15. Claims: partly 1-3, 16, 20-90, 161-168

  Emivirine-like phosphonate NNRTI compounds
- 16. Claims: 19, partly claims 1-3, 20-90, 161-168

  Loviride-like phosphonate NNRTI compounds
- 17. Claims: 18, partly claims 1-3, 20-90, 161-168
  UC781-like phosphonate NNRTI compounds
- 18. Claims: 140-147

  N-A2- imidazole derivatives
- 19. Claims: 148-160
   N-A1- imidazole derivatives
- 20. Claims: partly claims 1, 161-168

  NNRTI compounds containing phosphonate group(s) not comprised by inventions I-XIX
- 21. Claims: 225-228, 233-236

	International Application No. PCT/US 03 /12926
FURTHER INFORMATION CONTINUED FROM PCT	7/ISA/ 210
Method of targeting a com compound being not necess of such compound	mpound to white blood cells; the sarily a NNRTI and the preparation
·	

	<del></del>				Publication
Patent document cited in search report		Publication date		Patent family member(s)	date
WO 0196329	Α	20-12-2001	AP	200302716 DO	31-03-2003
			AU	6273301 A	24-12-2001
			BR	0111678 A	03-06-2003
			CA	2410763 A1	28-11-2002
			CN	1446213 T	01-10-2003
			CZ	20023940 A3	14-05-2003
			EP	1295879 A1	26-03-2003
			WO	0196329 A1	20-12-2001
			NO 	20026013 A	13-02-2003
WO 0203997	Α	17-01-2002	AU	7367001 A	21-01-2002
			CA	2405798 A1	17-01-2002
			CN	1440292 T	03-09-2003
			CZ	20024052 A3	12-03-2003
			EP	1303282 A1	23-04-2003
			HU	0301614 A2	29-09-2003 03-01-2003
			NO	20030033 A	01-04-2003
			SK WO	112003 A3 0203997 A1	17-01-2002
				U2U3997 KI	
US 6312662	<b>B1</b>	06-11-2001	US	2002052345 A1	02-05-2002
			AU	3069999 A	20-09-1999
			CA	2322487 A1	10-09-1999
			EP	1060182 A2	20-12-2000
			JP	2002505333 T	19-02-2002
			WO	9945016 A2	10-09-1999 
US 5413996	Α	09-05-1995	US	5177064 A	05-01-1993
			US	5618803 A	08-04-1997
			AT	150759 T	15-04-1997
			AU	649466 B2	26-05-1994 04-02-1992
			AU	8300091 A 2087194 A1	14-01-1992
			CA DE	69125377 D1	30-04-1997
			EP	0539493 A1	05-05-1993
			JP	5509313 T	22-12-1993
			WO	9200988 A1	23-01-1992
WO 0117982	A	15-03-2001	AU	7774300 A	10-04-2001
MO 011/205	А	13 03 2001	BR	0013771 A	14-05-2002
			CA	2383782 A1	15-03-2001
			CN	1391565 T	15-01-2003
			CZ	20020807 A3	17-07-2002
			WO	0117982 A1	15-03-2001
			EP	1208091 A1	29-05-2002
			HU	0202593 A2	28-12-2002
			JP	2003510252 T	18-03-2003
			NO	20021042 A	30-04-2002
			TR	200201187 T2	21-08-2002
EP 0786455	A	30-07-1997	AU	706095 B2	
	=		AU	4788896 A	19-04-1996
			BR	9509024 A	30-09-1997
			EP	0786455 A1	30-07-1997
			FI	971234 A	23-05-1997
			JP	3155009 B2	09-04-2001
			NO PL	971306 A 320009 A1	21-05-1997 01-09-1997

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0786455 /		US 5910506 A CA 2200316 A1 CN 1158609 A ,B HU 77357 A2 WO 9610019 A1 RU 2157368 C2 TW 401404 B US 6147097 A	08-06-1999 04-04-1996 03-09-1997 30-03-1998 04-04-1996 10-10-2000 11-08-2000 14-11-2000